PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology
Reference37 articles.
1. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer;Audeh;J. Clin. Oncol.,2009
2. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma;Bedikian;Cancer Invest.,2009
3. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions;Beneke;Int. J. Cancer,2004
4. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis;Bernstein;Mutat. Res.,2002
5. How do real tumors become resistant to cisplatin?;Borst;Cell Cycle,2008
Cited by 78 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PET imaging of PARP expression using 68Ga-labelled inhibitors;European Journal of Nuclear Medicine and Molecular Imaging;2023-05-05
2. Long non-coding RNA mediated drug resistance in breast cancer;Drug Resistance Updates;2022-07
3. Novel nanomedicines to overcome cancer multidrug resistance;Drug Resistance Updates;2021-09
4. The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction;European Journal of Medicinal Chemistry;2020-10
5. Molecular Mechanism of Selective Binding of NMS-P118 to PARP-1 and PARP-2: A Computational Perspective;Frontiers in Molecular Biosciences;2020-04-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3